Executive Search for Medical Technology

A medical device is rarely just a device. It consists of hardware, embedded or standalone software and a defined clinical application that brings all three levels together. An imaging system, for example, only delivers value if hardware, evaluation software and the clinical workflow in the clinic or practice are smoothly integrated. It is precisely this link that determines the eligibility, reimbursement and willingness of users to actually use the product.

Added value is generated over the entire product life cycle: conception, development, clinical evaluation, approval, serial production, sales, service, post-market surveillance and finally orderly replacement. Leadership in medical technology is thus less the question of who builds the most elegant technology, but who controls this chain industrially reliable, regulatoryly clean and economically viable.

The European regulations for medical devices (MDR) and in vitro diagnostic medical devices (IVDR) define uniform requirements for classification, clinical evidence, technical documentation, post-market surveillance and roles such as the person responsible for regulatory compliance [1][2]. For manufacturers, this means permanent effort – not only for new products, but over the entire stock.

The operational bracket is EUDAMED, the European database for medical devices. Since 28. Four modules of EUDAMED — Actor registration, UDI/Device registration, Notified Bodies and Certificates and Market Surveillance — are mandatory for manufacturers, authorised representatives, importers and other stakeholders [3]. The central component is the Unique Device Identification (UDI): The UDI clearly identifies products and registers them in EUDAMED, greatly simplifying traceability, recalls and market surveillance [4].

This shifts responsibility for management: Regulatory affairs, quality management, IT and supply chain work together more closely than ever before, and governance issues such as data quality, vigilance processes and traceability become top priorities.

A large part of European medical technology is medium-sized, often family-run and strongly attached to individual personalities. When generations of founders or owners hand over operational leadership, historically grown culture and new governance requirements meet: professionalized boards, investment partners, MDR-driven processes and international sales structures.

Family succession in medical technology therefore usually requires two role profiles at the same time - an operational management that continues the existing operation in a regulatoryly clean manner, and a commercial or international management that builds access to other national markets. Where sales have so far mainly been carried out via distributors or a few direct markets, the establishment of own national subsidiaries, clear market access strategies and robust reporting structures will become the central management task.

Those who take over leadership in medical technology work permanently in the triangle of R&D, quality and market. R&D is responsible for roadmap, software architecture, hardware design and integration of clinical use cases. Quality and regulation carry out technical documentation, clinical evaluation, cooperation with notified bodies and continuous demonstration of conformity in the field.

The market — hospitals, outpatient providers, shopping communities, payers — increasingly demands evidence of benefit, total cost of ownership, and digital integration capability. Leaders must be able to decide which product development is worthwhile, which portfolio adjustment is necessary and how sales organizations are set up along indications, countries or customer segments. Isolated engineering or sales perspective is usually not enough for this.

A reliable search process in medical technology goes beyond the CV. Among other things, documented responsibility for MDR or IVDR compliance of specific product classes, experience with notified bodies and audits, guided UDI and EUDAMED registration processes, responsibility for post-market surveillance and vigilance systems as well as experienced transitions between owner-managed and institutionalized governance are to be examined.

Equally important are the commercial realities: Who has actually established international sales structures, who has converted distributor into direct sales, who knows reimbursement dynamics in the relevant target markets? References with former supervisors, peers and report recipients as well as certified aptitude diagnostics where appropriate complement the picture with leadership, decision-making under uncertainty and dealing with regulatory pressure.

Firstly, a regulatory milestone is imminent — MDR recertification, IVDR transition, introduction of new EUDAMED modules — and the current governance structure clearly does not carry it.

Secondly, the owner-managed era is transformed into a structured succession, and advisory boards and new shareholders expect professionalized reporting and clear departmental design.

Thirdly, the leap from a home market to several international direct markets is imminent, without having experienced leadership in sales, regulation or supply chain.

Fourthly, a portfolio is to be cleaned up or expanded with software and digital health components, while the existing management is predominantly hardware-driven.

Fifth: Board or advisory board note that decisions between R&D, quality and market are regularly made too late or without a reliable factual basis.

Medical technology is one of the most regulated and at the same time internationally growing sub-sectors of the healthcare market. MDR, IVDR, EUDAMED and UDI permanently shift responsibility to top management; Succession, internationalization and the transformation towards software and data-based applications do the rest. Those who fill key positions in this environment need a search process that ranks technology, regulation and market equally — and a consultant who is familiar with this reality from more than 300 mandates in the healthcare market.